This case describes a person treated with the Lymphocyte-activation gene 3 (LAG-3) inhibitor relatlimab and the Programmed cell death protein 1 (PD-1) inhibitor nivolumab for stage IV melanoma who subsequently developed four distinct and significant toxicities. This evidence concerns the gene LAG3 and melanoma.